An open, randomized study was carried out to compare the efficacy of ciprofloxacin, 250 mg twice daily, and ofloxacin, 200 mg twice daily, in hospitalized patients with lower respiratory tract infections such as bacterial exacerbation of chronic bronchitis or community-acquired pneumonia. Fifty patients were treated in each group. The duration of treatment was 10 to 12 days. Microbiological examinations were carried out on sputum samples taken before, during and after treatment. In both groups, the clinical results were considered to be excellent, with clinical cure in 98% of the patients treated with ciprofloxacin and in 90% of patients treated with ofloxacin. Eradication of the initial sputum isolate was achieved in 98% of the patients of the ciprofloxacin group and in 82% of the patients of the ofloxacin group.

Adolescent↗

PubMedDate not supplied

[4-year-observation of results of VM 26 treatment of pathologic syndromes from the lymphoma malignum group].

The authors used the preparation VM 26 in 66 patients with various pathological syndromes belonging to the group of malignant lymphoma. The patients were divided into three groups. Group A received only VM 26, group B VM 26 and ultracorten, group C VM 26, cyclophosphamide, methylhydrazine and glycocorticosteroids. In all observed groups a therapeutic activity of VM 26 was demonstrated. The best therapeutic results were obtained in group C, in group B they were slightly worse.

Adult↗

PubMedDate not supplied

[Evaluation of anti-emetic action of domperidone in patients treated with cytostatics].

Domperidone was administered to 40 patients with various neoplastic syndromes to prevent nausea and vomiting observed during previous courses of chemotherapy. It was found, that daily dose of 30 mg completely prevents nausea and vomiting in 30% of patients and significantly lowers such symptoms in further 58% of patients. An increase in a daily dose of 60 mg abolishes nausea and vomiting in 60%, and decrease their intensity in 35% of patients. Domperidone was administered orally during the whole period of chemotherapy without any adverse reactions related to its anti-dopamine actions.

Adult↗

PubMedDate not supplied

[Preliminary observations on the results of treating malignant lymphoma with Lycurim].

The authors gave Lycurim to 30 patients with malignant lymphoma (LLC--12 cases, Hodgkin's disease - 15 cases, reticulosarcoma - 2 cases and lymphosarcoma - 1 case). The patients were divided into three groups. Group I received only Lycurim, group II - Lycurim and prednisone, group III - Lycurim and Solcoseryl. Significant improvement was observed in 22 patients, with complete remission in 5 cases and partial in 17 cases. Leucopenia and thrombocytopenia precluding treatment were never observed in cases treated simultaneously with prednisone or Solcoseryl. The authors believe that the proportion of remissions may be increased combining Lycurim with vincristine, procarbazine and glycocorticosteroids (LOP or LOPP).

Actihaemyl↗

PubMedDate not supplied

[A few years of following up results of chronic respiratory infections with broncho-vaxom].

Broncho-Vaxom was administered to 57 patients with chronic respiratory infections. A significant improvement was noted in 70% of the treated patients whereas mild improvement in 21%. Discussing the results of Broncho-Vaxom therapy, the author suggests so-called maintenance therapy with the same preparation to stabilize its effect.

Adjuvants, Immunologic↗

PubMedDate not supplied

[Results of ciprofloxacin therapy in urinary and respiratory tract infections].

Ciprofloxacin was administered to 218 patients with various urinary and respiratory tracts infections, including 142 patients with urinary tract infections and 76 patients with respiratory tract infections. Bacteriological tests and routine laboratory tests were performed thrice (before, during and after therapy) in all patients. Ciprofloxacin was administered orally in daily dose of 500 mg for 10 days. Daily dose was increased to 1000 mg in 23 patients with severe respiratory tract infections. Satisfactory results (recovery or regression of the symptoms of exacerbated chronic disease) were achieved in 185 patients (84.9%) and no effect in 10 patients (4.6%). Significant improvement or transient improvement were noted in 23 patients (10.5%).

Adult↗

PubMedDate not supplied

[Usefulness of beta-glucuronidase activity determination in the differential diagnosis of acute leukemia].

In 95 cases of acute leukemias the cytochemical type was determined according to Löffler's classification and the activity of beta-glucuronidase was determined in blast cells. In the light of these investigations it was demonstrated that determination of the activity of this enzyme may be useful only in the differential diagnosis and classification of certain cases of acute lymphoblastic or undifferentiated-cell leukaemias.

Acute Disease↗